ReviewCurrent opinion in immunology2011
Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.
Review in Current opinion in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.Cancer discovery · 2013Trial
- Expamers: a new technology to control T cell activation.Scientific reports · 2020Article
- Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.British journal of cancer · 2019Article
- Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.Leukemia · 2016Article
- Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.Oncoimmunology · 2016Article
- Coupling of HIV-1 Antigen to the Selective Autophagy Receptor SQSTM1/p62 Promotes T-Cell-Mediated Immunity.Frontiers in immunology · 2016Article
- Comprehensive analysis of the T-cell receptor beta chain gene in rhesus monkey by high throughput sequencing.Scientific reports · 2015Article
- The prognostic influence of tumor infiltrating Foxp3(+)CD4(+), CD4(+) and CD8(+) T cells in resected non-small cell lung cancer.Journal of inflammation (London, England) · 2015Article
- Chimeric antigen receptor modified T cell therapy for B cell malignancies.International journal of hematology · 2014Review
- Nanoscale artificial antigen presenting cells for T cell immunotherapy.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Human cell-based artificial antigen-presenting cells for cancer immunotherapy.Immunological reviews · 2014Review
- Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.Oncology letters · 2013Article
- CD4 T-cell immunotherapy for chronic viral infections and cancer.Immunotherapy · 2013Review
- Review
- Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.Cancer research · 2013Article
- Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Article
- Novel serial positive enrichment technology enables clinical multiparameter cell sorting.PloS one · 2012Article
- The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The extraordinary sensitivity and specificity of T cells for their cognate antigen make them a highly attractive cancer therapeutic. However, the rarity of tumor-reactive T cells in cancer patients, the difficulty isolating them in sufficient numbers for adoptive immunotherapy, and the unpredictable persistence of transferred cells have been significant obstacles to broad application. Technologies that enable genetic modification of T cells have been refined and are being used to redirect the specificity of T cells to tumor antigens. An issue the field is now grappling with is how the diverse phenotypic and functional heterogeneity in T cells that could potentially be genetically modified can be capitalized upon to enhance the efficacy, safety, and reproducibility of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.